Experimental Study Of Expression Of CD25 And Its MRNA Induced By IFN-α2b In PBMC In Patients With Chronic Hepatitis B

Objective To explore the expression of CD25 and CD25 mRNA and the effect of IFN-α2b on inducement to CD25 and its mRNA in PBMC of the patients with chronic hepatitis B.Methods The total of 249 patients with chronic hepatitis B in five groups (slight 93, moderate 67, severe 22, compensative cirrhosis 46, decompensative cirrhosis 21) were selected. The HBV markers in serum of patients were detected by enzyme-linked immunosorbent assay (ELISA). The copies of HBV-DNA in PBMC and serum of patients were detected by PCR. Before and after being stimulated with PHA, the expression of CD25 and its mRNA in PBMC of patients were detected by biotin-streptavidin (BSA) and Real-time PCR and RT-PCR, respectively. Each of groups (slight group and moderate group) was randomly divided into two subgroups and treated with IFN-α2b or routine medicine. The treatment lasted 48 weeks, and a course of treatment was 16 weeks. The level of CD25 and its mRNA before and after being stimulated with PHA were dynamically detected by same methods above. The HBV markers in serum were dynamically detected by ELISA. The copies of HBV-DNA in PBMC and serum were dynamically detected by PCR. Meanwhile, patient's liver function was dynamically testedResults The level of CD25 and its mRNA of PBMC either in silence or in inducement by PHA was lower in patients than that in normal controls (P<0.05 or P<0.01). The expression of CD25 and its mRNA was also lower in double positive of HBV-DNA in serum and PBMC than that in positive of HBV-DNA in serum or PBMC. However, there was little discrepancy among them (P>0.05). Meanwhile, there was significant difference between in everyone of them and in the normal control group (P<0.05 or P<0.01). The expression of CD25 and its mRNA could be increased after treatment of IFN-α2b and approached to that of the normal group. After the treatment of IFN-α2b for three courses of treatment, there was significant difference between in the subgroup of IFN (slight group and moderate group) and in the subgroup of routine medicine (P<0.05). In our study, as if the expression of CD25 mRNA was paralleled with that of CD25. There was significant difference between in the subgroup of IFN (slight group and moderate group) and in the subgroup of routine medicine in total negative rates of HBV-DNA in PBMC, serum and that of HBeAg, seroconversion of HBeAg (P<0.01 or P<0.05). After the treatment of IFN-α2b, the down-values of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the ratio of ALT and AST were highly significant difference between in subgroup of IFN (slight group and moderate group) and subgroup of routine medicine (P<0.01 or P<0.05). Conclusions The immune function is low in the patients with chronic hepatitis B, and low level of CD25 and its mRNA of PBMC has been associated with pathogenetic condition and infected place of HBV-DNA of patients. The expression of CD25 and its mRNA of PBMC in patients can be induced by IFN-α2b so that a lot of active T lymphocytes can be activated. Meanwhile, IFN-α2b has better therapeutic effect on HBV-DNA in PBMC, serum than that of routine therapy, and induces the negative change of HBeAg and seroconversion of HBeAg, and improves hepatic function of patients obviously.